NCT05833672View on ClinicalTrials.gov

Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Colon CancerImmunotherapy
Interventions
DRUG

Terelizumab

q3w Terelizumab 200mg on day 1 of each cycle

DRUG

CapeOx

Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days

Trial Locations (1)

400042

Daping hospital, Chongqing

All Listed Sponsors
lead

fan li

OTHER

NCT05833672 - Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers | Biotech Hunter | Biotech Hunter